• Explore /
  • Poster
  • / Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.

Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.

Abstract Video & Slides Poster

Authors

null

Masatoshi Kudo

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan

Masatoshi Kudo , Kazuomi Ueshima , Shin Nakahira , Naoshi Nishida , Hiroshi Ida , Yasunori Minami , Takuya Nakai , Hiroshi Wada , Shoji Kubo , Kazuyoshi Ohkawa , Asahiro Morishita , Takeo Nomi , Koji Ishida , Shogo Kobayashi , Makoto Umeda , Masakatsu Tsurusaki , Yasutaka Chiba , Kenichi Yoshimura , Kazuko Sakai , Kazuto Nishio

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

000026648

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4070)

DOI

10.1200/JCO.2021.39.15_suppl.4070

Abstract #

4070

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Masatoshi Kudo

First Author: Jared Cohen

First Author: Arndt Vogel

First Author: Edwin R. Parra